KURA - Kura Oncology files for $150M common stock offering mixed securities shelf
2023-11-03 08:02:08 ET
More on Kura Oncology
- Kura Oncology, Inc. 2023 Q3 - Results - Earnings Call Presentation
- Kura's Ziftomenib: The Swiss Army Knife In AML Therapy
- Kura Oncology, Inc. (KURA) Q2 2023 Earnings Call Transcript
- Kura Oncology GAAP EPS of -$0.50 beats by $0.05
- BofA starts Kura at buy, cites revenue potential of lead drug ziftomenib
For further details see:
Kura Oncology files for $150M common stock offering, mixed securities shelf